Leptin Protein (26-006897)
Closed Special Notice Posted
- Solicitation number
- 26-006897
- Agency
-
Office of Logisitics and Acquisition Operations
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Bethesda, Maryland 20817, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institutes of Health issued a Justification for Other Than Full and Open Competition on August 19, 2026, with a response deadline of August 26, 2026, announcing its intent to negotiate a sole-source purchase order with BIO-TECHNE SALES CORP for Recombinant Rat Leptin Protein. The Critical Care Medicine Department within the NIH Clinical Center requires this product for in vivo research under the ORWH Innovation Awards program examining sex and obesity-associated mechanisms and therapeutic targets in pulmonary arterial hypertension. The firm-fixed-price purchase order is valued at $34,272.85 and covers 10 vials of 80 milligram Recombinant Rat Leptin Protein and 5 vials of 1 milligram formulation, both at 0.00314 EU/g endotoxin levels in lyophilized standard formulation with PBS pH 7.4 buffer from lot AQP33. The justification asserts that Bio-Techne is the only responsible source capable of supplying this specific product because biological materials for animal treatments cannot be substituted without incurring additional testing, additional test subjects, validation delays, and compromised in vivo result comparability. Performance is scheduled for a 12-month period in fiscal year 2026. The contracting officer determined the price fair and reasonable; no market research identified alternative suppliers. The justification requires approval from the Division Director, NIH Head of the Contracting Activity, NIH Advocate for Competition, HHS Office of General Counsel, and HHS Advocate for Competition before final execution.
Notice text
The National Institute of Health (NIH) intends to negotiate and award a purchase order without
providing for full and open competition to BIO-TECHNE SALES CORP. The purpose of this requirement is to provide a firm-fixed-price contract for Recombinant Rat Leptin Protein in the Critical Care Medicine Department within the NIH Clinical Center.
The Critical Care Medicine Department conducts active research programs in bedside clinical investigation, research in animal models, and molecular biology.
Full-time research activities commence at the beginning of the second year of the fellowship for fellows interested in the critical care subspecialty alone. For those interested in dual board eligibility, their second-year program is individually designed and consists of clinical rotations required for board eligibility in the particular subspecialties. After completion of second subspecialty training, full-time research activities commence. Major topics of research interest within the Department include:
- The immunopathogenesis of septic shock
- Studies of immune cellular function in respiratory distress syndrome, asthma, and other forms of severe pulmonary disease
- Biomarkers and novel therapies in pulmonary arterial hypertension
- Biomarkers of acute cellular rejection in heart transplantation
- Diagnosis and treatment of opportunistic infections
- Studies of immune cellular function and therapy of AIDS
- Pathogenesis and treatment of anthrax
- Emerging infectious diseases
- Biology and clinical effects of nitric oxide
- acute lung injury
- pulmonary arterial hypertension
- role as transcription regulatory factor
- Functional genomics of critical illness
- human acute inflammation
- animal model of septic shock and multiple organ failure
- pulmonary arterial hypertension
- solid organ transplantation
- Emerging Infectious Disease
This product is a sole source item as it’s manufactured by the supplier. This material will be use on in vivo experiment under ORWH Innovation Awards SEX- AND OBESITY-ASSOCIATED MECHANISMS AND THERAPEUTIC TARGETS IN PULMONARY ARTERIAL HYPERTENSION. Biological material for animal treatments can’t be changed as we will incur in additional testing, additional testing subjects and validation and in vivo results can’t be compared.
Finally, a review of the GSA Advantage, Dynamic Small Business Search, and previous government acquisitions returned no results that meet all of the requirements. Therefore, only BIO-TECHNE SALES CORP. is capable of meeting the needs of this requirement.
Files
| File | Type | Posted |
|---|---|---|
| 26-006897 - JOFOC Leptin.docx | DOCX document |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity